WOMAN primary results, Lancet 2017
The main report of the WOMAN trial of tranexamic acid for bleeding after birth, published in The Lancet in 2017.
- Publication
- In this atlas
Overview
Technical summary
WOMAN Trial Collaborators. Lancet 2017;389(10084):2105-2116. doi:10.1016/S0140-6736(17)30638-4. PMID 28456509. PMC5446563 is the open-access version of record. An erratum (Lancet 2017;389(10084):2104, PMID 28483296) corrected the tranexamic acid concentration in the procedures section, which gave "10 mg/mL" where "100 mg/mL" was meant. The corrected text is online as of 5 May 2017, and the erratum text corrects only that concentration. This atlas reads the corrected version. Funding in the abstract includes Pfizer, which makes the tranexamic acid product used in the trial.
Bibliographic identity
- Type
- Article
- Source
- Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial
- Edition
- Abstract from PubMed (PMID 28456509). Full-text facts come from PMC5446563, the open-access version of record, which carries the online correction of 5 May 2017 described in maternal:woman-lancet-2017-erratum. Figure 3 (death from bleeding by subgroup) is a separate image on the PMC figure page, snapshotted as its own bytes because its numbers are not in the XML. The publication date is the print issue date; PubMed also lists an electronic date of 2017-04-26.
- Publisher
- Elsevier (The Lancet 389(10084):2105-2116)
- Published
- 2017-05-27
Record details
- Record id
maternal:pub-woman-lancet-2017- Content hash
41e6546c1e445223a06ef3a18f124da936de7b54dcb8126f3d9f9569d4ed144d